Kronos Bio, Inc. KRON
We take great care to ensure that the data presented and summarized in this overview for Kronos Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KRON
View all-
Vida Ventures Advisors, LLC2.77MShares$2.35 Million44.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$1.63 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.72MShares$1.46 Million0.0% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.22 Million0.1% of portfolio
-
Acadian Asset Management LLC Boston, MA1.3MShares$1.11 Million0.0% of portfolio
-
Wildcat Capital Management, LLC1.3MShares$1.1 Million0.49% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.17MShares$996,0360.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1MShares$852,8740.07% of portfolio
-
Black Rock Inc. New York, NY874KShares$742,9860.0% of portfolio
-
Siren, L.L.C. New York, NY843KShares$716,5100.04% of portfolio
Latest Institutional Activity in KRON
Top Purchases
Top Sells
About KRON
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Insider Transactions at KRON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Jun 28
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
204,670
+1.86%
|
$204,670
$1.25 P/Share
|
|
Jun 27
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
410,848
+3.73%
|
$410,848
$1.17 P/Share
|
|
Jun 25
2024
|
Elena Ridloff |
BUY
Grant, award, or other acquisition
|
Direct |
11,333
+30.94%
|
-
|
|
Jun 12
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
881,913
+10.68%
|
$881,913
$1.24 P/Share
|
|
Jun 11
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
744,308
+10.28%
|
$744,308
$1.09 P/Share
|
|
Jun 10
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
1,378,901
+19.34%
|
$0
$0.88 P/Share
|
|
Jun 03
2024
|
Deborah Knobelman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
164,260
+50.0%
|
-
|
|
Feb 21
2024
|
Elizabeth A Olek SR VP, CLINICAL SCIENCE |
SELL
Open market or private sale
|
Direct |
7,368
-3.67%
|
$7,368
$1.05 P/Share
|
|
Feb 21
2024
|
Allison Frisbee Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
12,105
-5.59%
|
$12,105
$1.05 P/Share
|
|
Feb 21
2024
|
Charles Y Lin Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,036
-4.88%
|
$12,036
$1.05 P/Share
|
|
Feb 15
2024
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
270,339
+8.77%
|
-
|
|
Jan 04
2024
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,366
-2.75%
|
$7,366
$1.18 P/Share
|
|
Jan 04
2024
|
Barbara Kosacz COO & General Counsel |
SELL
Open market or private sale
|
Direct |
10,676
-1.14%
|
$10,676
$1.18 P/Share
|
|
Jan 04
2024
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
12,009
-3.67%
|
$12,009
$1.18 P/Share
|
|
Dec 12
2023
|
Christopher Dinsmore Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,032
-3.6%
|
$10,032
$1.3 P/Share
|
|
Dec 12
2023
|
Jorge Di Martino Chief Medical Officer & VP |
SELL
Open market or private sale
|
Direct |
17,367
-5.04%
|
$17,367
$1.3 P/Share
|
|
Nov 17
2023
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
97,935
+3.71%
|
$97,935
$1.08 P/Share
|
|
Nov 16
2023
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
262,433
+9.7%
|
$262,433
$1.0 P/Share
|
|
Nov 15
2023
|
Norbert W Bischofberger PRESIDENT & CEO |
BUY
Open market or private purchase
|
Direct |
1,370,688
+38.6%
|
$0
$0.8 P/Share
|
|
Jul 06
2023
|
Yasir B. Al Wakeel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,617
-2.7%
|
$9,617
$1.75 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 176K shares |
|---|---|
| Open market or private purchase | 3.62M shares |